HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. ARWR | 0.00 |
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:
ARWR) with a Buy and raises the price target from $115 to $120.
